Sreedhar Mandayam is a Nephrology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 113 publications with 3,064 citations (h-index 27); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 77030
Telephone
713-792-6161Registry record last updated 28 Sept 2018.
Clinical trials
- CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells
Sponsor: Samuel Vilchez, PhD
- Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
Sponsor: M.D. Anderson Cancer Center
- Ferric Citrate in ESRD Pilot Project
Sponsor: Sreedhar Mandayam
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
48 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Calliditas Therapeutics US Inc.Program year202562 payments$57,938openpaymentsdata.cms.gov ↗
- KYOWA KIRIN, INC.Program year20259 payments
- Otsuka America Pharmaceutical, Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prevalence and Influence of Gout in Patients with Advanced Chronic Kidney Disease: Findings of a Large Retrospective Chart Review
Gout Urate and Crystal Deposition Disease
2024 - #1342 Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF/APRIL antagonist, in autoantibody-associated glomerulonephritis
Nephrology Dialysis Transplantation
2024 - Results from Longer Follow-Up with Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in IgA Nephropathy (RUBY-3 Study)
Journal of the American Society of Nephrology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”